Sorrento Therapeutics Inc logo

Sorrento Therapeutics Inc

FRA:8STN (USA)  
€ 0.30 (+19.2%) Mar 3
At Loss
Market Cap:
€ 163.34M ($ 176.00M)
Enterprise V:
€ 210.84M ($ 227.19M)
Volume:
-
Avg Vol (2M):
-
Also Trade In:

Business Description

Description
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Name Current Vs Industry Vs History
Cash-To-Debt 0.39
Equity-to-Asset -0.45
Debt-to-Equity -1.01
Debt-to-EBITDA -0.39
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -10.87
Distress
Grey
Safe
Beneish M-Score -3.37
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
6-1 Month Momentum % -56.39
12-1 Month Momentum % -57.25

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.5
Quick Ratio 0.47
Cash Ratio 0.3
Days Inventory 142.59
Days Sales Outstanding 150.64
Days Payable 295.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -45.3
Shareholder Yield % -2292.5

Financials (Next Earnings Date:2024-05-15 Est.)

FRA:8STN's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Sorrento Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 61.341
EPS (TTM) (€) -0.202
Beta 0
Volatility % 76.35
14-Day RSI 0
14-Day ATR (€) 0.12295
20-Day SMA (€) 0
12-1 Month Momentum % -57.25
52-Week Range (€) 0.1337 - 2.79
Shares Outstanding (Mil) 547.88

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Sorrento Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Sorrento Therapeutics Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Sorrento Therapeutics Inc Frequently Asked Questions

What is Sorrento Therapeutics Inc(FRA:8STN)'s stock price today?
The current price of FRA:8STN is €0.30. The 52 week high of FRA:8STN is €2.79 and 52 week low is €0.13.
When is next earnings date of Sorrento Therapeutics Inc(FRA:8STN)?
The next earnings date of Sorrento Therapeutics Inc(FRA:8STN) is 2024-05-15 Est..
Does Sorrento Therapeutics Inc(FRA:8STN) pay dividends? If so, how much?
Sorrento Therapeutics Inc(FRA:8STN) does not pay dividend.

Press Release

Subject Date
No Press Release